Trials / Completed
CompletedNCT01247194
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Presidio Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PPI-461 | capsule, oral, once daily for 3 days |
| DRUG | Placebo | capsules, oral, once daily for 3 days |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-05-01
- Completion
- 2011-06-01
- First posted
- 2010-11-24
- Last updated
- 2012-02-03
Locations
11 sites across 3 countries: United States, Denmark, United Kingdom
Source: ClinicalTrials.gov record NCT01247194. Inclusion in this directory is not an endorsement.